Status:
COMPLETED
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Infections, Herpesviridae
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- In overall general good health.
- HSV-2 (Herpes Simplex Virus-2) seropositive at screening.
- Exclusion criteria:
- have active lesions consistent with genital herpes.
- previous history of symptomatic genital herpes.
- history of recurrent, undiagnosed symptoms consistent with genital herpes.
Exclusion
Key Trial Info
Start Date :
March 29 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2006
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00116844
Start Date
March 29 2005
End Date
January 10 2006
Last Update
February 12 2018
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Carmichael, California, United States, 95608
2
GSK Investigational Site
Davis, California, United States, 95616
3
GSK Investigational Site
Riverside, California, United States, 92506
4
GSK Investigational Site
Sacramento, California, United States, 92585